Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

Eisai criticises NICE and CDF for rare cancer ‘black hole’ in England

July 8, 2016
Medical Communications, Research and Development CDF, Eisai, NICE, black hole

Japanese pharmaceutical company Eisai (TYO: 4523) has issued a statement expressing its dismay that advanced thyroid cancer patients in England …

News

Pfizer’s blood cancer drug first to be reappraised from Cancer Drug Fund

July 7, 2016
Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Pfizer, blood cancer, bosulif

The National Institute for Health and Care Excellence (Nice) recommended US pharma giant Pfizer’s (NYSE: PFE) Bosulif (bosutinib) to treat …

News

Nice rejects BMS’ immunotherapy Opdivo for previously treated kidney cancer on pricing

July 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, QALY, immunotherapy, opdivo, regulation

UK regulators have rejected Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy Opdivo for previously treated kidney cancer on pricing and substantial uncertainty …

News

Nice rejects AstraZeneca’s Tagrisso for lung cancer in preliminary recommendation

June 24, 2016
Medical Communications, Research and Development AstraZeneca, CDF, NICE, lung cancer, regulation

UK drugmaker AstraZeneca (LSE: AZN) said the National Institute for Health and Care Excellence (Nice) has rejected Tagrisso (osimertinib) to …

News
celgene_1_02

Nice rejects Celgene’s drug to treat blood cancer

June 24, 2016
Medical Communications, Research and Development CDF, Celgene, NICE, Vidaza, blood cancer

The National Institute for Health and Care Excellence (Nice) rejected biotech firm Celgene’s (Nasdaq: CELG) Vidaza (azacitidine) to treat a …

News
gsk_l_rgb

Interview: GSK’s subcutaneous formulation for Benlysta may help cut down hospital visits

June 22, 2016
Research and Development Benlysta, EULAR, Interview, Lupus, NICE, autoimmune diseases, drug trial

UK drugmaker GlaxoSmithKine (LSE: GSK) reported positive results for Benlysta following a late-stage study at the annual European Congress of …

Feature

Nice backs two cancer drugs from Novartis

June 22, 2016
Research and Development, Sales and Marketing AbbVie, Amgen, Humira, NICE, Novartis, Sanofi, lung cancer, skin cancer

The National Institute for Health and Care Excellence (Nice) has backed two drugs form Novartis (VTX: NOVN) for lung cancer …

News
nhs_sign

NHS looking to offer free healthcare apps, devices from next year

June 20, 2016
Medical Communications, Research and Development, Sales and Marketing DigitalHealth, HealthTech, NHS, NICE

The NHS will offer devices and apps for free to help patients manage their health, starting in UK next year.

News

Nice backs BMS’ combination immunotherapy Opdivo, Yervoy to treat skin cancer

June 17, 2016
Medical Communications, Research and Development, Sales and Marketing BMS, NICE, oncology, opdivo, regulation, skin cancer

The National Institute for Health and Care Excellence (Nice) has backed a combination of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) and …

News

Final Nice appraisal says no to cystic fibrosis drug, Orkambi

June 17, 2016
Medical Communications NICE, Orkambi, Vertex Pharma, cystic fibrosis, recommendation, regulation

The National Institute for Health and Care Excellence (Nice) has issued a final appraisal determination rejecting cystic fibrosis drug, Orkambi …

News
roche_close

Roche gets a NICE knockback for melanoma drug, Cotellic

June 16, 2016
Medical Communications, Research and Development, Sales and Marketing Cotellic, NICE, Roche

The National Institute for Health and Care Excellence (NICE) has announced that that it has not recommended Roche’s melanoma drug, …

News

Nice says Bayer’s Eylea not recommended as first-line treatment in draft recommendation

June 10, 2016
Medical Communications, Research and Development Bayer, Eylea, NICE, recommendation, regulation

The National Institute for Health and Care Excellence (Nice) in a provisional guidance said Bayer’s (ETR: BAYN) Eylea (aflibercept) is …

News
eli_lilly_logo

Nice does not recommend Eli Lilly’s lung cancer drug in draft guidance

May 26, 2016
Research and Development, Sales and Marketing Cancer Drugs Fund, Eli Lilly, NICE, lung cancer

The National Institute of Care and Excellence (Nice) did not recommend US drugmaker Eli Lilly’s (NYSE: LLY) Portrazza to treat …

News

NICE recommends Jevtana for advanced prostate cancer

May 25, 2016
Sales and Marketing Jevtana, NICE, approval, prostate cancer, recommendation

The National Institute for Health and Care Excellence (NICE) has recommended Sanofi Genzyme’s Jevtana (cabazitaxel), in combination with prednisone or …

News

Nice recommends three drugs to treat diabetes

May 25, 2016
Research and Development, Sales and Marketing AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, NICE, diabetes

The National Institute for Health and Care Excellence (Nice) has backed three drugs for the treatment of type 2 diabetes. …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026